Home
World
U.S.
Politics
Business
Movies
Books
Entertainment
Sports
Living
Travel
Blogs
Ambrx | search
Overview
Newspapers
Aggregators
Blogs
Videos
Photos
Websites
Click
here
to view Ambrx news from 60+ newspapers.
Bookmark or Share
Ambrx Info
Get the latest news about Ambrx from the top news
sites
,
aggregators
and
blogs
. Also included are
videos
,
photos
, and
websites
related to Ambrx.
Hover over any link to get a description of the article. Please note that search keywords are sometimes hidden within the full article and don't appear in the description or title.
Ambrx Photos
Ambrx Websites
Ambrx - Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a ...
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments. 10/23/2023. Newly published data from the Phase 1 portion of the on-going. Phase 1 / 2 APEX-01 trial provide the ...
Ambrx
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer 10/23/2023 Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in ...
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody ...
NEW BRUNSWICK, NJ (January 8, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug ...
Ambrx - Investor Relations
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.
Johnson & Johnson Completes Acquisition of Ambrx
Ambrx’s proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side effects typically associated with chemotherapy.
More
Ambrx Videos
CNN
»
NEW YORK TIMES
»
FOX NEWS
»
THE ASSOCIATED PRESS
»
WASHINGTON POST
»
AGGREGATORS
GOOGLE NEWS
»
YAHOO NEWS
»
BING NEWS
»
ASK NEWS
»
HUFFINGTON POST
»
TOPIX
»
BBC NEWS
»
MSNBC
»
REUTERS
»
WALL STREET JOURNAL
»
LOS ANGELES TIMES
»
BLOGS
FRIENDFEED
»
WORDPRESS
»
GOOGLE BLOG SEARCH
»
YAHOO BLOG SEARCH
»
TWINGLY BLOG SEARCH
»